Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design
Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design
复制标题
DOI：
10.1080/17425255.2020.1807936
复制
发表时间：
2020-08
影响因子：
4.3
通讯作者：
E. Sasaki;I. Hamaguchi;T. Mizukami
中科院分区：
文献类型：
--
作者：
E. Sasaki;I. Hamaguchi;T. Mizukami
摘要 简介 需要一种新的佐剂安全性和免疫原性评估系统。疫苗接种对于预防感染（例如流感病毒）很重要。佐剂被认为对于提高流感疫苗的有效性至关重要。佐剂开发是流感疫苗设计中的一个重要问题。涵盖领域 传统的疫苗安全性体内评估方法仅限于分析表型和病理变化。因此，很难获得分子水平上的变化信息。本综述旨在解释最近开发的基于基因组学分析的疫苗佐剂安全性评估工具，该工具通过 AddaVaxTM 和聚肌苷-聚胞苷酸 (poly I:C) 验证，使用 18 个生物标志物基因和全病毒粒子灭活流感疫苗作为毒性控制。基因组学分析将有助于通过促进适当的佐剂选择来提供有关流感疫苗设计的安全性和有效性信息。专家意见 使用基因组学技术的流感疫苗和佐剂的功效和安全性概况提供了有关免疫原性的有用信息，这与安全性和功效相关。该方法为选择适当的接种途径、疫苗抗原和佐剂的组合以及剂量提供了重要信息。通过基因组学分析评估疫苗佐剂的功效应通过未来使用各种疫苗的各种研究来验证。
ABSTRACT Introduction A novel adjuvant evaluation system for safety and immunogenicity is needed. Vaccination is important for infection prevention, for example, from influenza viruses. Adjuvants are considered critical for improving the effectiveness of influenza vaccines. Adjuvant development is an important issue in influenza vaccine design. Areas covered A conventional in vivo evaluation method for vaccine safety has been limited in analyzing phenotypic and pathological changes. Therefore, it is difficult to obtain information on the changes at the molecular level. This review aims to explain the recently developed genomics analysis-based vaccine adjuvant safety evaluation tools verified by AddaVaxTM and polyinosinic-polycytidylic acid (poly I:C) using 18 biomarker genes and whole-virion inactivated influenza vaccine as a toxicity control. Genomics analyzes would help provide safety and efficacy information regarding influenza vaccine design by facilitating appropriate adjuvant selection. Expert opinion The efficacy and safety profiles of influenza vaccines and adjuvants using genomics technologies provide useful information regarding immunogenicity, which is related to safety and efficacy. This approach provides important information to select appropriate inoculation routes, combinations of vaccine antigens and adjuvants, and dosing amounts. The efficacy of vaccine adjuvant evaluation by genomics analysis should be verified by various studies using various vaccines in the future.